Page 4 - Stock Analysis
Motilal Oswal initiates with 'Buy' on Rubicon Research; check target
Motilal Oswal has initiated coverage on Rubicon Research, a pharmaceutical manufacturing company, with a 'Buy' rating
 "Motilal Oswal initiates with 'Buy' on Rubicon Research; check target")
ITC set for steady recovery as cigarettes, FMCG offset Agri drag: Analysts
Brokerages were unanimous that the non-cigarette FMCG business remains a bright spot in ITC's portfolio.
 "ITC set for steady recovery as cigarettes, FMCG offset Agri drag: Analysts")
Earnings steady, valuations cheap: NTPC remains Nuvama's top power play
Nuvama has reiterated its 'Buy' rating, raising the sum-of-the-parts (SOTP)-based target price to ₹413 (from ₹401 earlier).
 "Earnings steady, valuations cheap: NTPC remains Nuvama's top power play")
Varun Beverages to distribute 'Carlsberg' in Africa: Analysts decode impact
Varun Beverages share price fell 2% after Q3CY25 results despite 19% profit growth. Analysts stay positive, citing Africa expansion, Carlsberg tie-up, and steady demand outlook.
 "Varun Beverages to distribute 'Carlsberg' in Africa: Analysts decode impact")
Coal India Q2 hit by weak volumes, high costs; brokerages split on outlook
Motilal Oswal, however, remained upbeat on Coal India, calling the earnings a 'big miss due to high costs' but maintaining its 'Buy' rating with a target price of ₹440.
 "Coal India Q2 hit by weak volumes, high costs; brokerages split on outlook")
Sustaining growth outperformance key for more gains in TVS Motor
TVS Motor posts record quarterly sales and strong earnings, driven by premium products and EV growth; brokerages stay bullish on sustained momentum and market share gains
 "Sustaining growth outperformance key for more gains in TVS Motor")
Strong Q2, EV gains power bullish view on TVS Motor Company; targets raised
The Street expects TVS Motor's consistent outperformance, new launches, and EV traction to sustain earnings momentum, even as some brokerage houses flag valuation concerns.
 "Strong Q2, EV gains power bullish view on TVS Motor Company; targets raised")
Growth revival in H2 key for Supreme Industries after weak Q2 show
Margins fell 160 bps in Q2 FY26 amid soft realisations, but analysts expect demand recovery in housing and agriculture to lift Supreme Industries' H2 performance
 "Growth revival in H2 key for Supreme Industries after weak Q2 show")
PNB Housing delivers steady Q2; analysts bullish on growth, margin outlook
On the bourses around 9:30 AM, PNB Housing share was trading flat at ₹927.45 apiece. By comparison, BSE Sensex was trading marginally higher at 84,792.25 levels.
 "PNB Housing delivers steady Q2; analysts bullish on growth, margin outlook")
New launch traction for Dr Reddy's key to offsetting price erosion
Given that price erosion in the North American market is expected to continue in the near term, some brokerages have cut their earnings estimates for the stock
 "New launch traction for Dr Reddy's key to offsetting price erosion")
InCred Equities upgrades Tata Steel to 'Add'; stock hits fresh 52-week high
On the bourses, Tata Steel shares rose as much as 1.91 per cent to hit a fresh 52-week high of ₹177.85 per share.
 "InCred Equities upgrades Tata Steel to 'Add'; stock hits fresh 52-week high")
InCred upgrades SAIL to 'Add', lifts target; stable outlook supports upside
Steel Authority's biggest competitive advantage remains its fully integrated raw material base, unlike private steelmakers such as Tata Steel or Jindal Steel and Power
 "InCred upgrades SAIL to 'Add', lifts target; stable outlook supports upside")
Steady growth, firm margins lift SBI Life to 52-wk high; analysts keep Buy
At 10 AM, SBI Life share price continued to trade in the northward direction, up 3.37 per cent at ₹1,902.60 per share. By comparison, BSE Sensex was trading 0.57 per cent higher at 84,695.60 levels.
 "Steady growth, firm margins lift SBI Life to 52-wk high; analysts keep Buy")
Brokerages see near-term upside in Dr Reddy's on Semaglutide, ex-US growth
Dr Reddy's Laboratories reported a consolidated Q2FY26 net profit of ₹1,437.2 crore, up 14 per cent Y-o-Y from ₹1,255.3 crore, with sequential growth largely flat.
 "Brokerages see near-term upside in Dr Reddy's on Semaglutide, ex-US growth")
Bharti Airtel finds its frequency: High Arpu, low capital expenditure
Margins ring loud as controlled spending and per-user revenue amplify financial signals for investors
 "Bharti Airtel finds its frequency: High Arpu, low capital expenditure")
Double whammy hits Colgate: GST cuts, competition weigh on Q2 sales
Analysts largely agree that the toothpaste major's volumes and revenue were hit by a 'double whammy' of GST rate cuts and intensifying competition, with limited signs of a near-term recovery.
 "Double whammy hits Colgate: GST cuts, competition weigh on Q2 sales")
Is Carysil your next growth stock? Anand Rathi says 'Buy', 28% upside eyed
Carysil is expanding beyond quartz and stainless steel sinks into built-in kitchen appliances and engineered surfaces
 "Is Carysil your next growth stock? Anand Rathi says 'Buy', 28% upside eyed")
Nuvama retains 'Hold' on Cipla, raises target after Eli Lilly diabetes deal
Cipla- Eli Lilly deal: Tirzepatide is a prescription drug used for managing type 2 diabetes and aiding weight loss in adults who are obese or overweight.
 "Nuvama retains 'Hold' on Cipla, raises target after Eli Lilly diabetes deal")
New launch pipeline, rental portfolio to boost Oberoi Realty's FY26 growth
The company reported pre-sales of Rs 1,299 crore for the September quarter, which was down 10 per cent year-on-year (Y-o-Y) due to a higher base last year
 "New launch pipeline, rental portfolio to boost Oberoi Realty's FY26 growth")
Why did YES Securities downgrade Dalmia Bharat to 'Sell'? Check target
Dalmia Bharat reported net profit of ₹239 crore in the September 2025 quarter (Q2FY25), up nearly fivefold from ₹49 crore in the year-ago period
 "Why did YES Securities downgrade Dalmia Bharat to 'Sell'? Check target")
